BioSpace News Archive

Genmab announced today that at a board meeting the board decided to grant 49,680 restricted stock units to members of the board of directors, management and employees of the company as well as the company’s subsidiaries and 139,597 warrants to management and employees of the company as well as the company’s subsidiaries.

Transgene will meet institutional investors from January 7 to 11, 2018, in San Francisco, USA, concurrent with the J.P. Morgan Healthcare conference.

The 2016 net sales of the products in France amount to around € 10 million.

BeiGene today announced that the first patient was dosed in a pivotal Phase 2 clinical trial of pamiparib in Chinese patients with advanced ovarian cancer.

Deciphera Pharma today announced that it has been added to the Russell 2000® Index, as part of Russell’s quarterly IPO additions, effective Friday, December 15, 2017, after market close.

EDAP TMS S.A. (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced the first HIFU treatments performed at Acibadem Hospital, Istanbul, Turkey, using the Company’s Focal One Robotic HIFU device.

Arch Therapeutics today announced that the Company has withdrawn its 510(k) notification for its medical device AC5 Topical Gel, from the FDA with plans to submit a new 510(k) as soon as possible following further discussion with the FDA.

Athenex today announced that it has been added to the NBI, which will be effective prior to market open today, Monday, December 18, 2017.

The primary efficacy endpoint of the study is the change in transferrin saturation, a standard measurement of iron levels in the body and one of the two key measurements used to detect iron overload, from baseline to end of treatment.

Interpace Diagnosticsi today announced that the Company has entered into a Laboratory Services Agreement with ARUP Laboratories, of Salt Lake City, Utah, whereby ARUP is utilizing Interpace Diagnostics as a laboratory services provider for its menu of molecular testing services.